scholarly journals A Role for OCT4 in Tumor Initiation of Drug-Resistant Prostate Cancer Cells

2010 ◽  
Vol 1 (9) ◽  
pp. 908-916 ◽  
Author(s):  
D. E. Linn ◽  
X. Yang ◽  
F. Sun ◽  
Y. Xie ◽  
H. Chen ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Cells ◽  
Drug Resistant ◽  
Tumor Initiation ◽  
Prostate Cancer Cells

scholarly journals Instructed‐assembly of small peptides inhibits drug‐resistant prostate cancer cells

2019 ◽  
Vol 112 (1) ◽  
Author(s):  
Zhaoqianqi Feng ◽  
Huaimin Wang ◽  
Meihui Yi ◽  
Chieh‐Yun Lo ◽  
Ashanti Sallee ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Cells ◽  
Drug Resistant ◽  
Prostate Cancer Cells ◽  
Small Peptides

scholarly journals Leptogorgins A–C, Humulane Sesquiterpenoids from the Vietnamese Gorgonian Leptogorgia sp.

Marine Drugs ◽  
2020 ◽  
Vol 18 (6) ◽  
pp. 310 ◽  
Author(s):  
Irina I. Kapustina ◽  
Tatyana N. Makarieva ◽  
Alla G. Guzii ◽  
Anatoly I. Kalinovsky ◽  
Roman S. Popov ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
South China Sea ◽  
Cancer Cells ◽  
South China ◽  
Absolute Configuration ◽  
Marine Invertebrates ◽  
Drug Resistant ◽  
Prostate Cancer Cells ◽  
First Report ◽  
Nmr Data

Leptogorgins A–C (1–3), new humulane sesquiterpenoids, and leptogorgoid A (4), a new dihydroxyketosteroid, were isolated from the gorgonian Leptogorgia sp. collected from the South China Sea. The structures were established using MS and NMR data. The absolute configuration of 1 was confirmed by a modification of Mosher’s method. Configurations of double bonds followed from NMR data, including NOE correlations. This is the first report of humulane-type sesquiterpenoids from marine invertebrates. Sesquiterpenoids leptogorgins A (1) and B (2) exhibited a moderate cytotoxicity and some selectivity against human drug-resistant prostate cancer cells 22Rv1.

scholarly journals Effective photodynamic therapy in drug-resistant prostate cancer cells utilizing a non-viral antitumor vector (a secondary publication)

LASER THERAPY ◽  
2016 ◽  
Vol 25 (1) ◽  
pp. 55-62 ◽  
Author(s):  
Masaya Yamauchi ◽  
Norihiro Honda ◽  
Hisanao Hazama ◽  
Shoji Tachikawa ◽  
Hiroyuki Nakamura ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Photodynamic Therapy ◽  
Cancer Cells ◽  
Drug Resistant ◽  
Prostate Cancer Cells

scholarly journals Glycolytic reprogramming through PCK2 regulates tumor initiation of prostate cancer cells

Oncotarget ◽  
2017 ◽  
Vol 8 (48) ◽  
pp. 83602-83618 ◽  
Author(s):  
Jiangsha Zhao ◽  
Jieran Li ◽  
Teresa W.M. Fan ◽  
Steven X. Hou
Keyword(s):  
Prostate Cancer ◽  
Cancer Cells ◽  
Tumor Initiation ◽  
Prostate Cancer Cells

Drug Accumulation Into Single Drug-Sensitive and Drug-Resistant Prostate Cancer Cells Conducted on the Single Cell Bioanalyzer

2014 ◽  
Author(s):  
Avid Khamenehfar ◽  
Ji Liu ◽  
Jia Cai ◽  
Michael Wong ◽  
Paul C. H. Li ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Single Cell ◽  
Cancer Cells ◽  
Drug Accumulation ◽  
Drug Resistant ◽  
Prostate Cancer Cells ◽  
Prostate Cell ◽  
Single Drug ◽  
Drug Molecules ◽  
Fluorescent Molecules

Multidrug resistance (MDR) occurs in prostate cancer, and this happens when the cancer cells resist chemotherapeutic drugs by pumping them out of the cells. MDR inhibitors such as cyclosporin A (CsA) can stop the pumping and enhance the drugs accumulated in the cells. The cellular drug accumulation is monitored using a microfluidic chip mounted on a single cell bioanalyzer. This equipment has been developed to measure accumulation of drugs such as doxorubicin (DOX) and fluorescently labeled paclitaxel (PTX) in single prostate cancer cells. The inhibition of drug efflux on the same prostate cell was examined in drug-sensitive and drug-resistant cells. Accumulation of these drug molecules was not found in the MDR cells, PC-3 RX-DT2R cells. Enhanced drug accumulation was observed only after treating the MDR cell in the presence of 5 μM of CsA as the MDR inhibitor. We envision this monitoring of the accumulation of fluorescent molecules (drug or fluorescent molecules), if conducted on single patient cancer cells, can provide information for clinical monitoring of patients undergoing chemotherapy in the future.

scholarly journals Fenofibrate Augments the Sensitivity of Drug-Resistant Prostate Cancer Cells to Docetaxel

Cancers ◽  
2019 ◽  
Vol 11 (1) ◽  
pp. 77
Author(s):  
Marcin Luty ◽  
Katarzyna Piwowarczyk ◽  
Anna Łabędź-Masłowska ◽  
Tomasz Wróbel ◽  
Małgorzata Szczygieł ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Drug Resistance ◽  
Cancer Cells ◽  
Combined Treatment ◽  
Metronomic Chemotherapy ◽  
Drug Resistant ◽  
Prostate Cancer Cells ◽  
Pc3 Cells ◽  
Effective Doses ◽  
Resistant Cells

Metronomic agents reduce the effective doses and adverse effects of cytostatics in cancer chemotherapy. Therefore, they can enhance the treatment efficiency of drug-resistant cancers. Cytostatic and anti-angiogenic effects of fenofibrate (FF) suggest that it can be used for the metronomic chemotherapy of drug-resistant prostate tumors. To estimate the effect of FF on the drug-resistance of prostate cancer cells, we compared the reactions of naïve and drug-resistant cells to the combined treatment with docetaxel (DCX)/mitoxantrone (MTX) and FF. FF sensitized drug-resistant DU145 and PC3 cells to DCX and MTX, as illustrated by their reduced viability and invasive potential observed in the presence of DCX/MTX and FF. The synergy of the cytostatic activities of both agents was accompanied by the inactivation of P-gp-dependent efflux, dysfunction of the microtubular system, and induction of polyploidy in DCX-resistant cells. Chemical inhibition of PPARα- and reactive oxygen species (ROS)-dependent pathways by GW6471 and N-acetyl-L-cysteine, respectively, had no effect on cell sensitivity to combined DCX/FF treatment. Instead, we observed the signs of adenosine triphosphate (ATP) deficit and autophagy in DCX/FF-treated drug-resistant cells. Furthermore, the cells that had been permanently propagated under DCX- and DCX/FF-induced stress did not acquire DCX/FF-resistance. Instead, relatively slow proliferation of DCX-resistant cells was efficiently inhibited by FF. Collectively, our observations show that FF reduces the effective doses of DCX by interfering with the drug resistance and energy metabolism of prostate cancer cells. Concomitantly, it impairs the chemotherapy-induced microevolution and expansion of DCX/FF-resistant cells. Therefore, FF can be applied as a metronomic agent to enhance the efficiency of palliative chemotherapy of prostate cancer.

Sign in / Sign up

Export Citation Format

Share Document